AZN Astrazeneca Earnings and EPS analysis

EPS in 2025 (TTM): $2.51

Last Report Period Date: Mar 31, 2025

As of June 2025, according to Astrazeneca's latest financial report, the company's current EPS (TTM) is $2.51. In 2024, the company recorded an earnings per share (EPS) of $2.27, which represents an increase compared to its EPS of $1.92 in 2023. Astrazeneca's earnings per share for the quarterly report ending on Mar 31, 2025 was $0.94.

The annual EPS in 2024 was $2.27, an increase of 18.2% from $1.92 in 2023. For the quarter ending Mar 31, 2025, the EPS was $0.94, showing a 32.4% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2025 is $2.51. In 2023, the annual EPS was $1.92, showing an increase of 81.1% from 2022.

Over the last 12 months, Astrazeneca has registered an EPS growth of 32.4% (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS growth rate of 284.3% per year over the past 3 years. Over the last 5 years, the company had an average EPS growth rate of 34.3%. A 10-year view shows that AZN has seen an average EPS growth of 16.6% per year.